Last reviewed · How we verify

NCT06114303: EPROMED

Ex-vivo Evaluation of the Effect of 2 Probiotic Solutions (Lactibiane ATB and Lactibiane Enfant) and 5 Classes of Drugs on the Intestinal Microbiota

Terminated Last updated 2 December 2025
What this trial tests

trial testing Stool sampling in Dysbiosis in 14 participants. Terminated before completion.

Timeline
14 March 2024
Primary endpoint
16 June 2025
16 June 2025

Quick facts

Lead sponsorLarena SAS
StatusTerminated
Study typeOBSERVATIONAL
Enrollment14
Start date14 March 2024
Primary completion16 June 2025
Estimated completion16 June 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Larena SAS

Who can join

Adults 1 to 40, female only, with Dysbiosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to test ex-vivo the effects of two probiotic solutions (Lactibiane ATB and Lactibiane Enfant) and five classes of drugs (antibiotic, proton pump inhibitor, non-steroidal anti-inflammatory, anxiolytic and anti-depressant) on microbial microcosms derived from human stool samples (from adults and children) re-cultured under anaerobic conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Stool sampling

Trials testing the same drug.

Other recruiting trials for Dysbiosis

Currently open trials in the same condition.

Other Larena SAS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06114303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing